• Experimental and Molecular Medicine
• /
• 제50권11호
• /
• pp.9.1-9.10
• /
• 2018

Although the positive effects of recombinant fibroblast growth factor-2 (rFGF-2) in chronic obstructive pulmonary disease (COPD) have been implicated in previous studies, knowledge of its role in COPD remains limited. The mechanism of FGF2 in a COPD mouse model and the therapeutic potential of rFGF-2 were investigated in COPD. The mechanism and protective effects of rFGF-2 were evaluated in cigarette smoke-exposed or elastase-induced COPD animal models. Inflammation was assessed in alveolar cells and lung tissues from mice. FGF-2 was decreased in the lungs of cigarette smoke-exposed mice. Intranasal use of rFGF-2 significantly reduced macrophage-dominant inflammation and alveolar destruction in the lungs. In the elastase-induced emphysema model, rFGF-2 improved regeneration of the lungs. In humans, plasma FGF-2 was decreased significantly in COPD compared with normal subjects (10 subjects, P = 0.037). The safety and efficacy of inhaled rFGF-2 use was examined in COPD patients, along with changes in respiratory symptoms and pulmonary function. A 2-week treatment with inhaled rFGF-2 in COPD (n = 6) resulted in significantly improved respiratory symptoms compared with baseline levels (P < 0.05); however, the results were not significant compared with the placebo. The pulmonary function test results of COPD improved numerically compared with those in the placebo, but the difference was not statistically significant. No serious adverse events occurred during treatment with inhaled rFGF-2. The loss of FGF-2 production is an important mechanism in the development of COPD. Inhaling rFGF-2 may be a new therapeutic option for patients with COPD because rFGF-2 decreases inflammation in lungs exposed to cigarette smoke.

• Tuberculosis and Respiratory Diseases
• /
• 제78권4호
• /
• pp.321-325
• /
• 2015

Background: The adverse effects of the phosphodiesterase-4 inhibitor roflumilast, appear to be more frequent in clinical practice than what was observed in chronic obstructive pulmonary disease (COPD) clinical trials. Thus, we designed this study to determine whether adverse effects could be reduced by starting roflumilast at half the dose, and then increasing a few weeks later to $500{\mu}g$ daily. Methods: We retrospectively investigated 85 patients with COPD who had taken either $500{\mu}g$ roflumilast, or a starting dose of $250{\mu}g$ and then increased to $500{\mu}g$. We analyzed all adverse events and assessed differences between patients who continued taking the drug after dose escalation and those who had stopped. Results: Adverse events were reported by 22 of the 85 patients (25.9%). The most common adverse event was diarrhea (10.6%). Of the 52 patients who had increased from a starting dose of $250{\mu}g$ roflumilast to $500{\mu}g$, 43 (82.7%) successfully maintained the $500{\mu}g$ roflumilast dose. No difference in factors likely to affect the risk of adverse effects, was detected between the dose-escalated and the discontinued groups. Of the 26 patients who started with the $500{\mu}g$ roflumilast regimen, seven (26.9%) discontinued because of adverse effects. There was no statistically significant difference in discontinuation rate between the dose-escalated and the control groups (p=0.22). Conclusion: Escalating the roflumilast dose may reduce treatment-related adverse effects and improve tolerance to the full dose. This study suggests that the dose-escalated regimen reduced the rate of discontinuation. However, longer-term and larger-scale studies are needed to support the full benefit of a dose escalation strategy.

• The Journal of Korean Physical Therapy
• /
• 제26권4호
• /
• pp.262-268
• /
• 2014

Purpose: This study was conducted in order to measure fatigue as an objective index, depression and health-related quality of life of patients with COPD in daily life, to understand the correlation between them, and to present reasons for using the results clinically. Methods: This study is intended to evaluate and compare depression, the health-related quality of life of each group after measuring lactic acid levels of 39 male patients with COPD, and dividing those with measurement values than the normal value into the experimental group, and those with normal values into the control group. Results: When comparing depression between the experimental group and the control group, it was measured at 10.38 in the experimental group, and at 7.00 in the control group (p<0.05). Health-related quality of life between the experimental group and the control group was measured at 51.8 in the experimental group, and at 48.67 in the control group (p>0.05). Conclusion: According to the results described above, it appears that patients with COPD have adapted to their disease in some degree for a long period of time, and they are physically and psychologically adjusting to the fatigue they experience, in their own ways of adapting. These results imply that improving physical activity is associated with relief of fatigue and improvement of the quality of life. Thus, there is a need for developing and researching an exercise program and a physical therapy intervention for enhancement of physical activity.

• 센서학회지
• /
• 제22권3호
• /
• pp.219-222
• /
• 2013

The exhaled breath contains gases generated from human body. When disease occurs in the body, exhaled breath may include gas components released from disease metabolism. If we can find specific elements through analysis of the exhaled gases, this approach is an effective way to diagnose the disease. The lung function has a close relationship with exhalation. Exhaled gases from COPD (Chronic Obstructive Pulmonary Disease) patients can be analyzed by gas chromatography-mass spectroscopy (GC-MS) and a gas sensor system. The exhaled breath for healthy person and COPD patients had different components. Significantly more benzendicarboxylic acid was detected from COPD patients than in healthy persons. In addition, patients had a variety of decane. Phosphorous compounds with different isomers were detected from patients. The results obtained by gas sensor system were processed by PCA (Principal Component Analysis). The PCA results revealed distinct difference between the patients and healthy people.

• Tuberculosis and Respiratory Diseases
• /
• 제46권3호
• /
• pp.317-326
• /
• 1999

연구목적: 호흡기에 대한 자율신경 기능도 기도 및 혈관의 평활근, 접막하선의 점액분비. 기관지 순환 혈류조절, 비만 세포의 염증 반응에 관계되는 매개물의 분비등 매우 다양하게 나타나며 이들 자율신경 장애는 기도 폐쇄의 원인으로 작용한다. 천식은 자율신경계 이상이 원인으로 작용하고 특히 부교감신경 기능 항진이 중요한 원인으로 알려져 있다. 저자들은 심혈관계와 호흡기 자율신경 지배가 공통적으로 일어난다는 사실을 기초로 비관혈적이고 안정한 심혈관 지율신경 검사를 실시하여 만성 폐쇄성 폐질환 환자에서 자율신경 장애유무를 알아보았다. 방 법: 대상은 영남대학교 의과대학 부속병원에서 만성 폐쇄성 폐질환으로 진단 받은 환자 20명과 건강진단 센터에서 건강한 것으로 판정 받은 비슷한 나이의 20명을 대조군으로 하였다. 만성 폐쇄성 폐질환은 American Thoracic Society의 정의를 따랐으며 허혈성 심장질환, 부정맥, 당뇨병, 중심성 및 말초성 신경질환 등과 같은 자율신경계에 영향을 미칠 수 있는 질환이 동반된 경우는 제외하였다. 자율신경검사는 Ewing과 Clarke의 방법을 사용하였으며 모든 대상에서 동맥혈 가스분석과 폐기능 검사를 동시에 실시하였다. 결 과: 만성 폐쇄생 폐질환 환자는 건강한 사랑에 비하여 빈번하게 자율신경 장애가 동반되어 있었으며 만성 폐쇄성 폐질환 환자에서 교감신경 장애보다 부교감신경 장애가 더 뚜렷하였다. 만성 폐쇄성 폐질환은 질병 이환 기간이 길거나, 흡연량이 많거나, 폐기능 검사상 $FEV_1$ 및 FVC 감소 정도가 심할수록 그리고 저산소혈증이 심한 경우에 자율신경 장애가 심하였으나 연령, 만성폐쇄성 폐질환의 종류 및 동맥혈 이산화탄소 분압과는 차이가 없었다. 결 론: 만성 폐쇄성 폐질환은 부교감신경 장애가 동반되어 있으며, 부교간신경 장애는 만성 폐쇄성 폐질환의 정도가 심할수록 더 뚜렷하게 나타났다. 이러한 부교감신경 장애는 만성 폐쇄성 폐질환의 원인으로 작용하기보다는 질병의 진행으로 인한 자율신경계의 기능 저하로 생각된다.

• Tuberculosis and Respiratory Diseases
• /
• 제69권6호
• /
• pp.434-441
• /
• 2010

Background: Chronic obstructive pulmonary disease (COPD) is a major health problem resulting in significant burden for patients and families. However, family caregivers' burden has not been well recognized. The objectives of this study were to evaluate the level of caregivers' burden and to explore the related factors based on family, patient, and social support factors. Methods: A face-to-face interview with 86 family caregivers who had been taking care of COPD patients was conducted. The participants answered a self-administered questionnaire. The questionnaire included the level of family caregivers' burden, health status and the relationship within the family, functional limitation of patients perceived by family caregivers and the social support. Results: The level of caregivers' burden among participants was considerably high. Risk factors for caregivers' burden included low educational level of family caregivers, low family income, hours of caregiving, and functional limitation of the patients. Protective factors for caregivers' burden were good relationship within the family and support from other family members or friends. Conclusion: It is proved that family caregivers are facing significant burden in taking care of COPD patients. To reduce family caregivers' burden, it is necessary to address socioeconomic status of the family and to provide various community resources including financial support and nursing services.

• Tuberculosis and Respiratory Diseases
• /
• 제84권2호
• /
• pp.96-104
• /
• 2021

Background: Many chronic obstructive pulmonary disease (COPD) patients receiving monotherapy continue to experience symptoms, exacerbations and poor quality of life. This study aimed to assess the efficacy and safety of direct switch from once-daily tiotropium (TIO) 18 ㎍ to indacaterol/glycopyrronium (IND/GLY) 110/50 ㎍ once daily in COPD patients in Korea. Methods: This was a randomized, open-label, parallel group, 12-week trial in mild-to-moderate COPD patients who received TIO 18 ㎍ once daily for ≥12 weeks prior to study initiation. Patients aged ≥40 years, with predicted post-bronchodilator forced expiratory volume in 1 second (FEV₁) ≥50%, post-bronchodilator FEV₁/forced vital capacity <0.7 and smoking history of ≥10 pack-years were included. Eligible patients were randomized in a 1:1 ratio to either IND/GLY or TIO. The primary objective was to demonstrate superiority of IND/GLY over TIO in pre-dose trough FEV₁ at week 12. Secondary endpoints included transition dyspnea index (TDI) focal score, COPD assessment test (CAT) total score, and rescue medication use following the 12-week treatment, and safety assessment. Results: Of the 442 patients screened, 379 were randomized and 347 completed the study. IND/GLY demonstrated superiority in pre-dose trough FEV₁ versus TIO at week 12 (least squares mean treatment difference [Δ], 50 mL; p=0.013). Also, numerical improvements were observed with IND/GLY in the TDI focal score (Δ, 0.31), CAT total score (Δ, -0.81), and rescue medication use (Δ, -0.09 puffs/day). Both treatments were well tolerated by patients. Conclusion: A direct switch from TIO to IND/GLY provided improvements in lung function and other patient-reported outcomes with an acceptable safety profile in patients with mild-to-moderate airflow limitation.

• 치위생과학회지
• /
• 제16권3호
• /
• pp.217-224
• /
• 2016

본 연구는 2009년 국민건강영양조사 자료를 이용하여 우리나라 성인에서 다양한 혼란변수를 보정한 후 현존자연치아수와 COPD와의 연관성을 알아보고자 하였다. 40세 이상 성인 3,107명을 대상으로 구강검진과 폐기능검사를 시행하여 다음과 같은 결론을 얻었다. 첫째, 폐기능검사에 의한 COPD 유병률은 11%였다. 현존자연치아수를 0~19개군, 20~27개군, 28개군으로 나누었을 때, COPD의 분포는 현존자연치아수가 0~19개인 군에서 21.0%로 가장 높았다. 둘째, COPD는 65세 이상군, 남자, 교육수준이 낮을수록, 정상적인 BMI를 갖는 군, 고혈압군에서 높았다(p<0.001). 셋째, 인구사회학적 특성, 사회경제적 위치, 건강관련행태, 구강건강 및 행태, 전신건강상태를 보정한 다중로지스틱 회귀분석에서는 현존자연치아수 20~27개군(OR, 1.90)과 0~19개군(OR, 3.93)에서 COPD와 연관성을 보여, 현존자연치아수가 적을수록 COPD의 위험이 증가함을 확인하였다. 특히 치주질환과 COPD의 중요한 위험요인인 흡연상태에 따른 층화분석결과, 현재흡연군에서만 모든 치아를 가지고 있는 군에 비해 0~19개 치아를 가진 군에서 OR이 8.90배 높은 결과를 보여 강한 연관성을 보여주었다(OR, 8.90; 95% CI, 2.53~31.33). 본 연구 결과를 통해 현존자연치아수는 COPD와 연관성이 있음을 확인하였다.

• Tuberculosis and Respiratory Diseases
• /
• 제60권6호
• /
• pp.631-637
• /
• 2006

배 경: 만성폐쇄성폐질환 환자의 호흡곤란은 일반적으로 폐활량에 반비례하나 유사한 폐기능에서도 서로 다른 호흡곤란을 호소한다. 본 연구는 만성폐쇄성폐질환 환자에서 우심실박출계수와 호흡곤란의 정도와 연관관계가 있는지를 알아보고자 한다. 방 법: 호흡곤란의 정도는 Medical Research Council (MRC) 호흡곤란척도로 분석하였고, MRC 4/5도인 중증군 24명과, MRC 2/3도인 중등증군 16명을 비교 분석하였다. 심전도게이트 일회통과법을 이용한 방사성동위원소 심조영술을 이용하여 우심실 박출계수를 구했으며, 안정시 동맥가스분석 및 폐기능검사를 시행하였다. 결 과: 기저 폐기능에서 잔기량의 예측치 평균이 (%) 중증군에서($210{\pm}87$) 중등증군($160{\pm}27$)에 비해 유의하게 증가되었으나(P < 0.03), 폐활량 및 확산계수 등에서는 유의한 차이가 관찰되지 않았다. 우심실 박출계수(%)는 중증군에서($25{\pm}8$) 중등증군($35{\pm}6$)에 비해 유의하게 감소되었으나(P < 0.001), 동맥혈가스는 두 군 사이에 유의한 차이가 관찰되지 않았다. 다중회귀분석을 통해 우심실 박출계수가 독립적으로 호흡곤란에 영향을 미치는 인자로 밝혀졌다. 결 론: 만성폐쇄성폐질환에서 우심실 박출계수가 호흡곤란의 정도에 영향을 미치는 것으로 보인다.

• Tuberculosis and Respiratory Diseases
• /
• 제86권1호
• /
• pp.33-46
• /
• 2023

Background: Umeclidinium/vilanterol (UMEC/VI; ANORO ELLIPTA, GSK) is a commonly used dual bronchodilator. This study evaluated the safety and effectiveness of UMEC/VI in Korean patients with chronic obstructive pulmonary disease (COPD) over a 6-year period. Methods: This was an open-label, multicentre, observational, post-marketing surveillance study. A total of 3,375 patients were enrolled consecutively in 52 hospitals, by 53 physicians, between July 2014 and July 2020. Patients who were administered UMEC/VI (fixed-dose 62.5 ㎍/25 ㎍) at least once and were monitored for safety and effectiveness were included in the analysis. Incidence and severity of adverse events (AEs) reported after administrating at least one dose of UMEC/VI were monitored, including unexpected adverse events (UAEs) and adverse drug reactions (ADRs). Effectiveness of UMEC/VI after 24 weeks of administration was also assessed using physician's evaluation (effective, ineffective/no change, worsening, indeterminable) and lung function improvement. Results: Of 3,375 patients, 3,086 were included in the safety assessment group (mean age±standard deviation: 69.76±8.80 years; 85.9% male [n=2,652]; 73.1% aged ≥65 years [n=2,255]). The overall incidence of AEs was 28.8% (n=890), of which 2.2% (n=67) were ADRs. Serious AEs and UAEs were reported in 181 (5.9%) and 665 (21.6%) patients, respectively, and two patients (<0.1%) reported unexpected severe ADR. Of the 903/3,086 patients analysed for effectiveness, most (82.8%, n=748) showed overall disease improvement after UMEC/VI treatment. Conclusion: This study confirmed UMEC/VI administered to Korean patients according to the prescribing information was well-tolerated and can be considered an effective option for COPD treatment.